<DOC>
	<DOCNO>NCT02796066</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness TSN 2898 topical gel treatment moderate severe acne .</brief_summary>
	<brief_title>TSN2898-201 Safety Efficacy TSN2898 Treatment Acne Vulgaris</brief_title>
	<detailed_description>TSN2898 inhibitor stearoyl-CoA desaturase-1 ( SCD-1 ) , enzyme present sebaceous gland key regulatory enzyme lipogenesis . This study ass safety efficacy TSN2898 topical gel match gel vehicle , apply daily face treatment moderate severe acne vulgaris .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Healthy male female , 16 55 year age Must diagnose moderate severe acne vulgaris ≥ 20 inflammatory lesion face ≥ 20 noninflammatory lesion face ≤ 3 nodule/cyst acne lesion Medically healthy Females must nonchildbearing potential Systemic therapy retinoids within six ( 6 ) month prior study start Topical use prescription retinoids within four ( 4 ) week prior study start Oral antibiotic within four ( 4 ) week prior study start Topical dapsone , sulfacetamide , benzoyl peroxide , αhydroxy/glycolic acid retinol/retinaldehydecontaining product , topical antibiotic , antiinflammatory medication corticosteroid face within two ( 2 ) week prior study start Facial procedure , include laser , peel , dermabrasion , within two ( 2 ) month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acne , topical , SCD-1 inhibitor , moderate , severe</keyword>
</DOC>